Arax Advisory Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Arax Advisory Partners’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300	Closed	-$266	–	1320
2022 Q4	$266	Sell	300 -100	-25%	-$133	﹤0.01%	1228
2022 Q3	$1K	Buy	400 +100	+33%	+$227	﹤0.01%	1198
2022 Q2	$1K	Hold	300	–	–	﹤0.01%	1147
2022 Q1	$1K	Hold	300	–	–	﹤0.01%	1140
2021 Q4	$1K	Hold	300	–	–	﹤0.01%	1122
2021 Q3	$2K	Hold	300	–	–	﹤0.01%	863
2021 Q2	$3K	Buy	+300	New	+$2.39K	﹤0.01%	825

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Arax Advisory Partners's SRNE Position: Q1 2023 in Review

Arax Advisory Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 300 shares — an estimated $266 sold.

Arax Advisory Partners first reported a position in SRNE in Q2 2021 and held it in 7 quarters. The position peaked at $3K in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Arax Advisory Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Arax Advisory Partners sold 300 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $266.
Arax Advisory Partners first reported a position in Sorrento Therapeutics, Inc. in Q2 2021 and held it in 7 quarters.
Arax Advisory Partners's Sorrento Therapeutics, Inc. position peaked at $3K in Q2 2021.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Arax Advisory Partners's 13F filing for Q1 2023, filed 16 May 2023.